GE HealthCare initiated with a Market Perform at BMO Capital
BMO Capital initiated coverage of GE HealthCare with a Market Perform rating and $70 price target. The innovation assets are "real" and Flyrcado and Photonova Spectra are "genuine long-term catalysts," the analyst tells investors. However, the firm believes two consecutive years of macro-driven guidance cuts have moved the stock into "show me" territory and it views the risk/reward as balanced at the current multiple, the analyst added.
BMO Capital initiated coverage of GE HealthCare with a Market Perform rating and $70 price target.
The innovation assets are "real" and Flyrcado and Photonova Spectra are "genuine long-term catalysts," the analyst tells investors.
However, the firm believes two consecutive years of macro-driven guidance cuts have moved the stock into "show me" territory and it views the risk/reward as balanced at the current multiple, the analyst added.